Oral News and Research

RSS

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

Mathematical models analyzing how a cholera outbreak spread in Zimbabwe are providing new insights into the most effective vaccination strategies for preventing future cholera epidemics, according to University of Florida researchers.

3 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Scientists identify protein sorting mechanism used by salivary gland

University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.

3 Jun 2011

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 on social impairment in adolescents and adults with fragile X syndrome.

2 Jun 2011

First Edition: June 2, 2011

Today's health policy headlines cover a gamut of develoments, including reports about the latest Medicare dust up in the ongoing budget negotiations and about oral arguments in the latest round of appellate court action related to health law legal challenges.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.

1 Jun 2011

Shield raises EUR8.2M through Series A financing

Shield Therapeutics, the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m from Inventages Venture Capital (Inventages) in its first institutional financing round.

1 Jun 2011

Government questions plantiff's standing in challenge to health law

The 6th Circuit Court of Appeals will hear oral arguments on the Thomas More Law Center case in Cincinnati tomorrow. Government lawyers say one of the plaintiffs lacks standing.

1 Jun 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

1 Jun 2011

School children with bullying behavior more likely to have sleep-disordered breathing

Children who are bullies or have conduct problems at school, are more likely to be sleepy during the day according to University of Michigan Medical School researchers.

1 Jun 2011

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

Moisturisers, hair dyes cause serious adverse effects

Permanent hair dye gives the most serious adverse effects, yet there are also many reactions to facial and body moisturisers. This comes from the first report from the National Register of Adverse Effects from Cosmetic Products published by the Norwegian Institute of Public Health.

31 May 2011

Radiant to expand consumer products testing capabilities

Radiant Research, Inc. today announced that it is expanding its consumer products testing capabilities through creation of a new division of Radiant Research devoted to consumer trial conduct.

31 May 2011

Ashland agrees to acquire ISP

Ashland Inc. and International Specialty Products Inc. today announced that Ashland has agreed to acquire privately owned ISP, a global specialty chemical manufacturer of innovative functional ingredients and technologies.

31 May 2011

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Davos Life Science has today announced preliminary results of a phase I clinical trial of its Natural e3 delta-tocotrienol (Natural e3) in patients with resectable pancreatic cancer. Tocotrienols are highly potent members of the Vitamin E family that have been found by researchers to inhibit the growth and survival of various types of cancer cells.

30 May 2011

CPS, AAP release joint statement on early childhood caries

Early childhood caries is a serious health problem in North American Indigenous communities that needs immediate attention, say the Canadian Paediatric Society and the American Academy of Pediatrics in a joint statement released today.

30 May 2011

Oral News and Research

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Scientists identify protein sorting mechanism used by salivary gland

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

First Edition: June 2, 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Shield raises EUR8.2M through Series A financing

Government questions plantiff's standing in challenge to health law

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

School children with bullying behavior more likely to have sleep-disordered breathing

Birth control pill safety issues raised

Moisturisers, hair dyes cause serious adverse effects

Radiant to expand consumer products testing capabilities

Ashland agrees to acquire ISP

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

CPS, AAP release joint statement on early childhood caries

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News